medigraphic.com

2017, Number 2

<< Back Next >>

Rev Med MD 2017; 8.9 (2)

Macular edema and diabetic retinopathy in primary care

Lonngi-Ardila M, Duque-Ramírez JJ, Infante de Germán-Ribón R, Rodríguez-Alvira FJ, Lewis AJ, Mogollón I

Language: Spanish
References: 42
Page: 214-220
PDF size: 579.14 Kb.


ABSTRACT

We present the case of a 64 year old patient with one year history of progressive vision loss and medical history of diabetes mellitus type 2 and hypertension, both with irregular control; who is diagnosed with severe non-proliferative diabetic retinopathy and bilateral moderate to severe macular edema. The diagnostic methods used, treatment, clinical course and outcome are exposed, as well as a review of the literature directed mainly at primary care physicians, emphasizing the importance of early screening for this disease.


REFERENCES

  1. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012 Aug;12(4):346–54.

  2. Fraser CE, D'Amico DJ. Classification and clinical features of diabetic retinopathy. Uptodate. 2013. p. Topic 1783 Version 7.0.

  3. Targher G, Bertolini L, Zenari L, Lippi G, Pichiri I, Zoppini G, et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabet Med. 2008 Jan;25(1):45–50.

  4. Scholl S, Augustin A, Loewenstein A, Rizzo S, Kupperman B. General pathophysiology of macular edema. Eur J Ophthalmol. 2011 Jan;21 Suppl 6:S10-9.

  5. Schubert HD. 2012-2013 Basic and Clinical Science Course, Section 12: Retina and Vitreous. San Francisco, USA: American Academy of Ophthalmology; 2012.

  6. Zechmeister-Koss I, Huic M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: asystema ticre ew. BrJOphtha l m o l . 2012 Feb;96(2):167–78.

  7. Lang GE. Diabetic macular edema. Ophthalmologica. 2012 Jan;227 Suppl(suppl 1):21–9.

  8. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556–64.

  9. Simó R, Hernández C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care. 2009 Aug;32(8):1556–62.

  10. Koo NK, Jin HC, Kim KS, Kim YC. Relationship between the morphology of diabetic macular edema and renal dysfunction in diabetes. Korean J Ophthalmol. 2013 Apr;27(2):98–102.

  11. Diep TM, Tsui I. Risk factors associated with diabetic macular edema. Diabetes Res Clin Pract. 2013 Jun;100(3):298–305.

  12. Kramer CK, de Azevedo MJ, da Costa Rodrigues T, Canani LH, Esteves J. Smoking habit is associated with diabetic macular edema in Type 1 diabetes mellitus patients. J Diabetes Complications. 2008 Jan;22(6):430.

  13. Zur D, Fischer N, Tufail A, Monés J, Loewenstein A. Postsurgical cystoid macular edema. Eur J Ophthalmol. 2011 Jan;21 Suppl 6(Vol. 21 Suppl. 6- Steroids and Macular Edema):S62-8.

  14. Dowler J G, Hykin PG, Hamilton AM. Phacoemulsification versus extracapsular cataract extraction in patients with diabetes. Ophthalmology. 2000 Mar;107(3):457–62.

  15. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009 Mar;116(3):497–503.

  16. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BEK. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology. 2008 Nov;115(11):1859–68.

  17. Gallego PH, Craig ME, Hing S, Donaghue KC. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ. 2008 Jan;337:a918.

  18. Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003 Jun;26(6):1731–7.

  19. Zhang X, Saaddine JB, Chou C-F, Cotch MF, Cheng YJ, Geiss LS, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA. 2010 Aug;304(6):649–56.

  20. Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 2010 May;88(3):279–91.

  21. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984 Apr;102(4):527–32.

  22. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology. 1991 May;98(5 Suppl):786–806.

  23. Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 2003 Jul;136(1):122–35.

  24. Virgili G, Menchini F, Murro V, Peluso E, Rosa F, Casazza G, et al. Optical coherence tomography ( OCT ) for detection of macular oedema in patients with diabetic retinopathy ( Review ) Optical coherence tomography ( OCT ) for detection of macular oedema in patients with diabetic retinopathy. 2011;(7).

  25. Schimel AM, Fisher YL, Flynn HW. Optical coherence tomography in the diagnosis and management of diabetic macular edema: timedomain versus spectral-domain. Ophthalmic Surg Lasers Imaging. 2011 Jul;42 Suppl:S41-55.

  26. Sayegh RG, Georgopoulos M, Geitzenauer W, Simader C, Kiss C, Schmidt-Erfurth U. Highresolution optical coherence tomography after surgery for vitreomacular traction: a 2-year followup. Ophthalmology. 2010 Oct;117(10):2010–7, 2017- 2.

  27. Gallemore RP, Jumper JM, McCuen II BW, Jaffe GJ, Postel EA, Toth CA. Diagnosis of vitreoretinal adhesions in macular disease with optical coherence tomography. Retina. 2000;20:115–20.

  28. Chen T, Cense B, Pierce M. Spectral domain optical coherence tomography: ultra-high speed, ultra-high resolution ophthalmic imaging. Arch Ophthalmol. 2005;(123):1715–1720.

  29. Nassif N, Cense B, Park B et al. In vivo highresolution video-rate spectral-domain optical coherence tomography of the human retina and optic nerve. Opt Express. 2004;(12):367–376.

  30. Bottós JM, Elizalde J, Rodrigues EB, Maia M. Current concepts in vitreomacular traction syndrome. Curr Opin Ophthalmol. 2012;(23):195–201.

  31. Oishi A, Shimozono M, Mandai M, Hata M, Nishida A, Kurimoto Y. Recovery of photoreceptor outer segments after anti-VEGF therapy for agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012 May;

  32. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010 Jul;376(9735):124–36.

  33. OPS. Guías ALAD de diagnóstico, control y tratamiento de la Diabetes Mellitus Tipo 2. Asoc Latinoam Diabetes. 2006;1–80.

  34. Of S, Care diabetes M. Standards of Medical Care in Diabetes 2016. Am Diabetes Assos siation. 2016;39(January).

  35. Sinclair SH, Delvecchio C. The internist's role in managing diabetic retinopathy: screening for early detection. Cleve Clin J Med. 2004;71(2):151–9.

  36. Giuliari GP. Diabetic retinopathy: current and new treatment options. Cur r Diabetes Rev. 2012 Jan;8(1):32–41.

  37. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993 Sep;329(14):977–86.

  38. Thomas BJ, Shienbaum G, Boyer DS, Flynn HW. Evolving strategies in the management of diabetic macular edema: clinical trials and current management. Can JO phthalmol. 2013 Feb;48(1):22–30.

  39. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985 Dec;103(12):1796–806.

  40. Wang H, Sun X, Liu K, Xu X. Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and metaanalysis of randomized clinical control trials. Curr Eye Res. 2012 Aug;37(8):661–70.

  41. Comyn O, Lightman SL, Hykin PG. Corticosteroid intravitreal implants vs. ranibizumab for the treatment of vitreoretinal disease. Curr Opin Ophthalmol. 2013 May;24(3):248–54.

  42. Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane database Syst Rev. 2012 Jan;12(4):CD007419.




2020     |     www.medigraphic.com